Warpspeed — Forecasts
warpspeed.sh · 3,553 words · saved by 1 readers
Clinical trial forecasts powered by Monte Carlo simulation
Open (Prediction of future trial): 10 PREVAIL: Obicetrapib in Atherosclerotic Cardiovascular Disease Forecast 37% P(success) Hazard Ratio, 4P-MACE0.90[0.82 – 0.99] 0.700.800.901.001.101.20 Forecast: 37% probability of success on the primary 4-point MACE endpoint, with a simulated hazard ratio of 0.90 corresponding to roughly a 10% reduction in major cardiovascular events. Thesis: Three independent approaches to estimating obicetrapib's effect, grounded in its lipid-lowering profile and the CETP class track record from REVEAL, all converge on a modest ~10% event reduction, but PREVAIL…
saved by
related reading
- Gap Mapgap-map.org
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Can Machine Learning Give Us Faster and Cheaper Clinical Trials?substack.com
- Cure all diseasesworksinprogress.news
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- The Promise and Impact of the Next Generation of Weight Loss Drugsmetaculus.com
- OCTO - Noetiknoetik.ai
- Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalsstatnews.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Clinic-in-the-Loopasimov.press
- AI-Powered Drug Discovery Platform | Deep Origindeeporigin.com
- Unmet Needs Index — Biopharma Disease Prioritizationinsights.convoke.bio